News | December 15, 2025
Eiko LifeSciences to acquire 51% stake in SSM Formulations
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
The companies aim to expand treatment options for millions living with metabolic disorders
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Subscribe To Our Newsletter & Stay Updated
